Ridgewood Investments’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-200
Closed -$35.9K – 321
2025
Q2
$35.9K Sell
200
-660
-77% -$115K 0.02% 380
2025
Q1
$146K Hold
860
– – 0.07% 210
2024
Q4
$130K Sell
860
-321
-27% -$49.9K 0.06% 210
2024
Q3
$183K Sell
1,181
-10
-0.8% -$1.49K 0.09% 179
2024
Q2
$163K Buy
+1,191
New +$163K 0.08% 194
2023
Q3
– Sell
-614
Closed -$86.2K – 319
2023
Q2
$86.2K Hold
614
– – 0.05% 252
2023
Q1
$86.8K Sell
614
-701
-53% -$100K 0.05% 270
2022
Q4
$206K Sell
1,315
-692
-34% -$99.4K 0.15% 177
2022
Q3
$246K Buy
2,007
+149
+8% +$19.6K 0.2% 144
2022
Q2
$247K Hold
1,858
– – 0.19% 151
2022
Q1
$254K Hold
1,858
– – 0.17% 159
2021
Q4
$321K Hold
1,858
– – 0.2% 140
2021
Q3
$270K Sell
1,858
-748
-29% -$109K 0.18% 152
2021
Q2
$344K Sell
2,606
-43
-2% -$5.63K 0.22% 134
2021
Q1
$340K Buy
2,649
+845
+47% +$104K 0.21% 139
2020
Q4
$207K Hold
1,804
– – 0.16% 154
2020
Q3
$207K Sell
1,804
-802
-31% -$94.8K 0.16% 155
2020
Q2
$297K Buy
+2,606
New +$276K 0.25% 126

Other funds holding DGX

Ridgewood Investments's DGX Position: Q3 2025 in Review

Ridgewood Investments sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 200 shares — an estimated $35.9K sold.

Ridgewood Investments first reported a position in DGX in Q2 2020 and held it in 18 quarters. The position peaked at $344K in Q2 2021. 1,006 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Ridgewood Investments reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Ridgewood Investments sold 200 Quest Diagnostics shares in Q3 2025, an estimated $35.9K.
  • Ridgewood Investments first reported a position in Quest Diagnostics in Q2 2020 and held it in 18 quarters.
  • Ridgewood Investments's Quest Diagnostics position peaked at $344K in Q2 2021.
  • 1,006 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Ridgewood Investments's 13F filing for Q3 2025, filed 30 Oct 2025.